Important Safety Update for XELJANZ^® (tofacitinib)

On Friday, December 3, 2021, the U.S. Food and Drug Administration (FDA) updated the XELJANZ full prescribing information. Pfizer issued a media statement announcing that the U.S. full prescribing information for XELJANZ^® (tofacitinib) has been updated based on the U.S. FDA’s completed review of the ORAL Surveillance trial, a post-marketing required safety study. Talk to your healthcare provider if you have any questions or concerns about this safety update. Your healthcare provider should consider the benefits and risks of XELJANZ.

The safety information below applies to all marketed formulations of XELJANZ. Specific risks associated with certain dosing are noted.

As a result of this review, an additional warning for Major Cardiovascular Events, and updated warnings for Mortality, Cancer, and Blood Clots were included in the Boxed Warning and related Warnings and Precautions section of the prescribing information and in the Most Important Information I Should Know section of the patient Medication Guide for XELJANZ.

The updated Boxed Warning information regarding Mortality discusses the increased risk of death in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor taking recommended doses of XELJANZ.

The updated Boxed Warning regarding cancer discusses a higher risk of certain cancers, including lymphoma and lung cancer in patients taking XELJANZ, especially if you are a current or past smoker. Tell your healthcare provider if you are a current or past smoker or have had any type of cancer.

The new Boxed Warning includes information regarding increased risk of major cardiovascular events such as heart attack, stroke, or death in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking recommended doses of XELJANZ, especially if you are a current or past smoker.

Patients taking XELJANZ should seek medical attention right away or get emergency help if you have any symptoms of a heart attack or stroke, including:

discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
pain or discomfort in your arms, back, neck, jaw, or stomach
shortness of breath with or without chest discomfort
breaking out in a cold sweat
nausea or vomiting
feeling lightheaded
weakness in one part or on one side of your body
slurred speech

The updated Boxed Warning regarding blood clots in the lungs (pulmonary embolism, PE), veins of the legs (deep vein thrombosis, DVT) and arteries (arterial thrombosis) discusses that blood clots have happened more often in patients who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking recommended doses of XELJANZ. Patients should tell their healthcare provider if they have had blood clots in the veins of their legs, arms, or lungs or clots in arteries in the past. Patients should always ask their doctors for medical advice about adverse events. You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (U.S. only). If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit https://www.fda.gov/MedWatch or call 1-800-FDA-1088.

The FDA approved use of XELJANZ for adults with moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and for children age 2 and over with polyarticular course juvenile idiopathic arthritis and now recommends use after one or more medicines called tumor necrosis factor (TNF) blockers did not work well or cannot be tolerated.

If you have any questions about these updates talk to your healthcare provider.

The updated Important Safety Information and Indications for XELJANZ are included below for your review.

It is also important to read the patient Medication Guide you receive with your XELJANZ prescriptions, which explains the important things you need to know about the medicine. These include side effects, what the medicine is used for, how to take and store it properly, and other things to watch for when you’re taking the medicine.

Information about Post-Marketing Safety Study

When the FDA first approved XELJANZ for adults with moderate to severe rheumatoid arthritis in 2012, the agency required a clinical safety trial to examine the risk for heart-related problems, cancer, and serious infections in XELJANZ compared to another type of medicine called tumor necrosis factor (TNF) blockers. This trial, known as Oral Surveillance enrolled 4,369 participants who were required to be at least 50 years of age and have at least one cardiovascular risk factor.

IMPORTANT SAFETY INFORMATION

The safety information below applies to all marketed formulations of XELJANZ. Specific risks associated with certain dosing are noted.

Serious infections. XELJANZ can lower the ability of your immune system to fight infections. Do not start taking XELJANZ if you have any kind of infection unless your healthcare provider tells you it is okay. Serious infections have happened in people taking XELJANZ. These serious infections include tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider should test you for TB before starting and during treatment with XELJANZ. You should not start taking XELJANZ if you have any kind of infection unless your healthcare professional tells you it is okay.

Before and after starting XELJANZ, tell your doctor if you have an infection or symptoms of an infection, including:

fever, sweating, or chills
cough
blood in phlegm
warm, red, or painful skin or sores on your body
burning when you urinate
urinating more often than normal
muscle aches
shortness of breath
weight loss
diarrhea or stomach pain
feeling very tired

Increased risk of death in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking XELJANZ 5 mg twice daily or XELJANZ 10 mg twice daily.

Cancer. XELJANZ may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers, including skin cancers, can happen. People taking XELJANZ 5 mg twice daily or XELJANZ 10 mg twice daily have a higher risk of certain cancers including lymphoma and lung cancer, especially if you are a current or past smoker. Tell your healthcare provider if you have ever had any type of cancer.

Higher dose. People with ulcerative colitis taking the higher dose of XELJANZ (10 mg twice daily) or XELJANZ XR (22 mg one time each day) have a higher risk of serious infections, shingles, or skin cancers.

Immune system problem. Some people who have taken XELJANZ with certain other medicines to prevent kidney transplant rejection have had a problem with certain white blood cells growing out of control (Epstein Barr Virus–associated post-transplant lymphoproliferative disorder).

Increased risk of major cardiovascular events such as heart attack, stroke or death in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking XELJANZ 5 mg twice daily or XELJANZ 10 mg twice daily, especially if you are a current or past smoker.

Get emergency help right away if you have any symptoms of a heart attack or stroke while taking XELJANZ, including:

discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
pain or discomfort in your arms, back, neck, jaw, or stomach
shortness of breath with or without chest discomfort
breaking out in a cold sweat
nausea or vomiting
feeling lightheaded
weakness in one part or on one side of your body
slurred speech

Blood clots in the lungs (pulmonary embolism, PE), veins of the legs (deep vein thrombosis, DVT), and arteries (arterial thrombosis) have happened more often in patients who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking XELJANZ 5 mg twice daily or XELJANZ 10 mg twice daily. Blood clots in the lungs have also happened in patients with ulcerative colitis. Some people have died from these blood clots.

Stop taking XELJANZ and tell your healthcare provider right away if you have any signs and symptoms of blood clots such as sudden shortness of breath, difficulty breathing, chest pain, swelling of a leg or arm, leg pain or tenderness, or red or discolored skin in the leg or arm.

Tears (perforation) in the stomach or intestines. Tell your healthcare provider if you have had diverticulitis (inflammation in parts of the large intestine) or ulcers in your stomach or intestines. Some people taking XELJANZ can get tears in their stomach or intestine. This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate. Tell your healthcare provider right away if you have fever, stomach-area pain that does not go away, and a change in your bowel habits.

Serious allergic reactions can occur. Stop using XELJANZ and call your healthcare provider right away if you have swelling of your lips, tongue, throat, or get hives.

Changes in certain lab test results. Your doctor should do blood tests to check your white and red blood cells before and while you are taking XELJANZ. Your doctor should also check certain liver tests. You should not receive XELJANZ if your lymphocyte count, neutrophil count, or red blood cell count is too low or your liver function test levels are too high. Changes in lab test results may cause your healthcare provider to stop your XELJANZ treatment for a time. Your cholesterol levels should be checked 4 to 8 weeks after you start receiving XELJANZ.

Before you use XELJANZ, tell your healthcare provider if you:

Are being treated for an infection, have an infection that won’t go away or keeps coming back, or think you have symptoms of an infection
Have TB, or have been in close contact with someone with TB, or were born in, lived in, or traveled where there is more risk for getting TB
Have diabetes, chronic lung disease, HIV, or a weak immune system. People with these conditions have a higher chance for infections
Live or have lived in certain areas (such as Ohio and Mississippi River Valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections
Have or have had Hepatitis B or C
Are a current or past smoker
Have had any type of cancer
Have had a heart attack, other heart problems or stroke
Have had blood clots
Have liver or kidney problems
Have any stomach area (abdominal) pain or been diagnosed with diverticulitis or ulcers in your stomach or intestines
Have recently received or plan to receive a vaccine. People taking XELJANZ should not receive live vaccines but can receive non-live vaccines
Are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed. You should not take XELJANZ and breastfeed
Have had a reaction to tofacitinib or any of the ingredients
Are taking other medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take any of the following medicines while taking XELJANZ since this may increase your risk of infection:
- tocilizumab (Actemra^®)
- etanercept (Enbrel^®)
- adalimumab (Humira^®)
- infliximab (Remicade^®)
- rituximab (Rituxan^®)
- abatacept (Orencia^®)
- anakinra (Kineret^®)
- certolizumab (Cimzia^®)
- golimumab (Simponi^®)
- ustekinumab (Stelara^®)
- secukinumab (Cosentyx^®)
- vedolizumab (Entyvio^®)
- sarilumab (Kevzara^®)
- azathioprine, cyclosporine, or other immunosuppressive drugs
Tell your healthcare provider if you are taking medicines that affect the way certain liver enzymes work. Ask your healthcare provider if you are not sure if your medicine is one of these.

What are other possible side effects of XELJANZ/XELJANZ XR?

If you are a carrier of the Hepatitis B or C virus (viruses that affect the liver), the virus may become active while you use XELJANZ. Your healthcare provider may do blood tests before starting and while using treatment with XELJANZ. Tell your healthcare provider if you have any signs of these symptoms: feel very tired, little or no appetite, clay-colored bowel movements, chills, muscle aches, skin rash, skin or eyes look yellow, vomiting, fevers, stomach discomfort, or dark urine.

Common side effects in adults with rheumatoid arthritis and psoriatic arthritis include upper respiratory tract infections (common cold, sinus infections), headache, diarrhea, nasal congestion, sore throat, runny nose (nasopharyngitis), and high blood pressure (hypertension).

Common side effects in adults with ulcerative colitis include nasal congestion, sore throat, runny nose (nasopharyngitis), increased cholesterol levels, headache, upper respiratory tract infections (common cold, sinus infections), increased muscle enzyme levels, rash, diarrhea, and shingles (herpes zoster).

Common side effects in children (2 & older) with polyarticular course juvenile arthritis include upper respiratory tract infections (common cold, sinus infections), nasal congestion, sore throat, and runny nose (nasopharyngitis), headache, fever, nausea, and vomiting.

XELJANZ & Pregnancy

XELJANZ may affect the ability of females to get pregnant. It is not known if this will change after stopping XELJANZ. It is not known if XELJANZ will harm an unborn baby.

Pregnancy Registry: Pfizer has a registry for pregnant women who take XELJANZ. The purpose of this registry is to check the health of the pregnant mother and her baby. If you are pregnant or become pregnant while taking XELJANZ, talk to your healthcare provider about how you can join this pregnancy registry or you may contact the registry at 1-877-311-8972 to enroll.

You and your healthcare provider should decide if you will take XELJANZ or breastfeed. You should not do both. After you stop your treatment with XELJANZ do not start breastfeeding again until 18 hours after your last dose of XELJANZ or 36 hours after your last dose of XELJANZ XR.

What is XELJANZ/XELJANZ XR/XELJANZ Oral Solution?

XELJANZ/XELJANZ XR (tofacitinib) is used to treat adults with:

Moderately to severely active rheumatoid arthritis when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or cannot be tolerated
Active psoriatic arthritis when 1 or more tumor necrosis factor (TNF) blocker medicines have been used, and did not work well or cannot be tolerated
Moderately to severely active ulcerative colitis when 1 or more tumor necrosis factor (TNF) blocker medicines have been used, and did not work well or cannot be tolerated

XELJANZ/XELJANZ Oral Solution is used to treat patients 2 years of age and older with:

Active polyarticular course juvenile arthritis when 1 or more tumor necrosis factor (TNF) blocker medicines have been used, and did not work well or cannot be tolerated

It is not known if XELJANZ/XELJANZ XR is safe and effective in people with Hepatitis B or C.

XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended for people with severe liver problems.

It is not known if XELJANZ/XELJANZ Oral Solution is safe and effective in children for treatment other than active polyarticular course juvenile arthritis.

It is not known if XELJANZ XR is safe and effective in children.

Please see full Prescribing Information, including BOXED WARNING and Medication Guide.

patients in focus

A Closer Look at Real Patient Stories

We reached out to the following adult patients with moderate to severe RA, active PsA, or moderate to severe UC who were prescribed XELJANZ after TNF blockers did not work well or could not be tolerated. Learn about their journeys on XELJANZ by exploring their stories below. Individual results may vary. Patient ambassador stories have been created in partnership with Pfizer.

The impact of XELJANZ

Because of her RA symptoms, Ronda found it harder to do the things that she loves to do. She tried methotrexate and then TNF blockers, but she did not receive enough relief. Her doctor suggested XELJANZ as an option, and they discussed the benefits and serious side effects. A couple of weeks after starting on XELJANZ, Ronda noticed an improvement in her joint pain and swelling.*

*In clinical trials, it took up to three months or longer for some patients to see improvement. Individual results may vary.

“I just kept working on it a little bit at a time, and it was done.”

With XELJANZ, Ronda has been able to manage her RA symptoms. For her, finding an effective treatment wasn’t just about feeling better physically, but also about feeling well enough to be able to complete the handmade heirlooms she wanted to share with her family.

Maybe one treatment doesn’t work for you, but … keep trying. Just never give up.
- Ronda

Ronda in focus

Ronda’s passions are quilting and baking, but she also enjoys swimming, gardening, and walking her dog. Above all else, Ronda loves spending time with her granddaughters. On most days you’ll find her outdoors or getting something done around the house.

Ready to talk to your doctor? Find out more about XELJANZ to see if it could be right for you. Learn More

Meet Alison

Diagnosis: Moderate to severe rheumatoid arthritis

Alison has been living with moderate to severe RA since she was 19. At that time, she relied on her mother’s support, but since becoming a mother herself, Alison wondered how much her RA diagnosis could impact her daughter’s life. Alison tried different medications—including a TNF blocker, but still wasn’t having consistency in the management of her disease.

The impact of XELJANZ

Alison didn’t want to settle and talked to her doctor about her treatment plan. Alison and her doctor discussed the benefits and serious side effects of XELJANZ as a treatment option. They decided as a team that she would try XELJANZ. With XELJANZ, Alison noticed an improvement in her joint pain and stiffness over time.*

*Individual results may vary.

When you feel better, you want to share that with the ones you love and your family.
- Alison

“My mom was my support system”

With XELJANZ, Alison has been able to manage her RA symptoms. For her, finding an effective treatment wasn’t just about feeling better physically, but also about feeling well enough to share her experiences with her family. Alison was thankful that her mom was able to see her condition improve before she passed away.

Alison in focus

Alison likes creating many memories with her daughter—and one of her favorites is tending to their chicken coop. From gathering eggs to baking delicious cookies—Alison looks forward to the things she loves most, like enjoying time with her daughter.

Ready to talk to your doctor? Find out more about XELJANZ to see if it could be right for you. Learn More

The impact of XELJANZ

After Stephanie was diagnosed with moderate to severe UC, it took a while for it to sink in. She kept talking to her doctor to better understand what she was facing. Over the years, she was prescribed a series of different medications, including a TNF blocker, which eventually stopped working. Stephanie couldn’t get her symptoms under control—and felt like she was starting all over again. But she refused to settle. That’s when Stephanie and her doctor knew it was time to consider other treatment options and, after discussing the benefits and serious side effects, they decided she should try XELJANZ.

“Now, nobody’s worried about me having to sit down or run back home. So, it’s the simpler things that I really enjoy most.”

Stephanie noticed an improvement in her UC symptoms after a month of taking XELJANZ. After a while, she was seeing less blood in her stool, less frequency and then eventually she was in remission.* With XELJANZ, Stephanie has been able to manage her UC symptoms—and is eager to start new adventures.

*Individual results may vary

Life goes in ups and downs. Someone told me once that the greater the down, the bigger the up is going to be. It's absolutely true.
- Stephanie

Stephanie in focus

Stephanie has an artist’s spirit and a heart for adventure. She enjoys everything from making jewelry to planning trips to places she’s always imagined exploring. She believes that a creative spark of inspiration can ignite anywhere—a dream. An emotion. But to Stephanie, life’s best moments are the simple things: walking her dogs, visiting family, even doing common household chores. She’s looking forward to finding more inspiration in her life.

Ready to talk to your doctor? Find out more about XELJANZ to see if it could be right for you. Learn More

Meet Lisa

Diagnosis: Moderate to severe rheumatoid arthritis

Lisa loves going off the beaten path and taking in the local experiences when she travels. When she was diagnosed with moderate to severe RA, she wondered about the impact of her condition on activities she enjoys, like traveling. Lisa started taking methotrexate, but her symptoms of joint pain and swelling progressed. Then, Lisa tried a TNF blocker, but it didn't work well enough.

The impact of XELJANZ

After reading an article about XELJANZ, Lisa decided to ask her doctor about it as a treatment option. After discussing the benefits and serious side effects with her doctor, Lisa started on XELJANZ. Her RA symptoms began to improve within several weeks.^* She noticed less swelling in her hands and eventually helped her to feel less fatigue from her RA.

*In clinical trials, it took up to three months or longer for some patients to see improvement. Individual results may vary.

I’m looking forward to creating some new memories.
- Lisa

Lisa wanted to do and enjoy more

At the time of her diagnosis, Lisa’s kids were in middle school and she was looking forward to high school graduations, proms, and traveling. For her, the most important thing was creating new memories with her family.

Be kind to yourself. Show as much grace to yourself as you can afford to others. It’s okay to say, “No, maybe next time,” without feeling guilty.- Lisa

Ready to talk to your doctor? Find out more about XELJANZ to see if it could be right for you. Learn More

The impact of XELJANZ

Patti loves to bake, so she was heartbroken when her symptoms made it difficult to roll out pie crust for Thanksgiving dinner. After Patti and her doctor discussed the benefits and serious side effects of XELJANZ, her doctor prescribed XELJANZ along with a nonbiologic DMARD. After several weeks, Patti reported less joint pain and swelling.*

*In clinical trials, it took up to three months or longer for some patients to see improvement. Individual results may vary.

“Being able to do what I enjoy means so much to me.”

With XELJANZ, Patti has been able to manage her active PsA symptoms. Patti is thankful that her symptoms have improved—by advocating for herself, now she can care for others again.

So, if you feel there is something wrong, keep pushing until you find the answer.
- Patti

Patti in focus

Patti is not only a nurse, she's also a whiz in the kitchen. Brownies. Cookies. Cakes. Pies. You name it, Patti bakes it. For her, baking brings back fond memories of spending time with her grandmother—and the hope she'll be able to pass those memories down to her own grandchildren when the time comes.

Ready to talk to your doctor? Find out more about XELJANZ to see if it could be right for you. Learn More

Quote

If you feel something’s wrong, keep pushing until you find an answer.- Patti

Quote

Learn more about Patti

Living with active PsA

Quote

Living with moderate to severe RA

Quote

Learn about Lisa’s travels

Living with moderate to severe RA

Real Patient Stephanie

Living with moderate to severe UC

Learn how Stephanie saw symptom improvement with her moderate to severe UC

See more of Stephanie’s story

Living with moderate to severe UC

Quote

When you feel better, you want to share that with the ones you love and your family. - Alison

Quote

Learn more about Alison

Living with Moderate to severe RA

Quote

Living with active PsA

Quote

Alison's family time

Living with moderate to severe RA

Quote

Living with moderate to severe RA

See Patti talk about her nursing career

Hear more of Patti’s story

Living with active PsA

Ronda in snow with dog

Living with moderate to severe RA

Quote

I’m looking forward to creating some new memories. - Lisa

Quote

Learn more about Lisa

Living with moderate to severe RA

Black and white chicken

Meet Alison's chickens

Living with moderate to severe RA

Quote

Living with moderate to severe RA

Hear how Lisa looks forward to creating new memories

Living with moderate to severe RA

Quote

After a TNF blocker did not work well enough, my doctor and I decided it was time to talk about other treatment options. - Stephanie

Quote

Learn more about Stephanie

Living with moderate to severe UC

Want to share
your XELJANZ
story? Become a
patient
ambassador.

Stephanie holding kitten

Stephanie in focus

Living with moderate to severe UC

Quote

Neither methotrexate nor TNF blockers gave me enough symptom relief. So my doctor and I decided I would try XELJANZ.- Ronda

Quote

Learn more about Ronda

Living with moderate to severe RA

Patti standing outdoors with husband

Living with active PsA

See why Ronda’s granddaughters mean the world to her

Hear more of Ronda’s story

Living with moderate to severe RA

Discover Support Resources

If you and your doctor are considering XELJANZ as a treatment option, sign up for our support program to receive information, lifestyle tips, and tools, and take an active role in your treatment.

Pill, hand, and glass

Pill, hand, and glass

Hand, pill, and glass

Indications

XELJANZ/XELJANZ XR (tofacitinib) is used to treat adults who have tried TNF blockers with:

Moderately to severely active rheumatoid arthritis when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or cannot be tolerated
Active psoriatic arthritis when 1 or more tumor necrosis factor (TNF) blocker medicines have been used, and did not work well or cannot be tolerated
Moderately to severely active ulcerative colitis when 1 or more tumor necrosis factor (TNF) blocker medicines have been used, and did not work well or cannot be tolerated
Active ankylosing spondylitis when 1 or more tumor necrosis factor (TNF) blocker medicines have been used, and did not work well or cannot be tolerated

XELJANZ/XELJANZ Oral Solution is used to treat patients 2 years of age and older with:

Active polyarticular course juvenile arthritis when 1 or more tumor necrosis factor (TNF) blocker medicines have been used, and did not work well or cannot be tolerated

It is not known if XELJANZ/XELJANZ XR is safe and effective in people with Hepatitis B or C.

XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended for people with severe liver problems.

It is not known if XELJANZ/XELJANZ Oral Solution is safe and effective in children for treatment other than active polyarticular course juvenile arthritis.

It is not known if XELJANZ XR is safe and effective in children.

XELJANZ/XELJANZ XR (tofacitinib) is used to treat adults who have tried TNF blockers with:

Moderately to severely active rheumatoid » Read More

Important Safety Information

Serious infections. XELJANZ can lower the ability of your immune system to fight infections. Do not start taking XELJANZ if you have any kind of infection unless your healthcare provider tells you it is okay. Serious infections have happened in people taking XELJANZ. These serious infections include tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider should test you for TB before starting and during treatment with XELJANZ. You should not start taking XELJANZ if you have any kind of infection unless your healthcare professional tells you it is okay.

Before and after starting XELJANZ, tell your doctor if you are being treated for an infection, have infections that keep coming back, or have symptoms of an infection, including:

fever, sweating, or chills
cough
blood in phlegm
warm, red, or painful skin or sores on your body
burning when you urinate
urinating more often than normal
muscle aches
shortness of breath
weight loss
diarrhea or stomach pain
feeling very tired

Increased risk of death in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking XELJANZ 5 mg twice daily or XELJANZ 10 mg twice daily.

Cancer. XELJANZ may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers, including skin cancers, can happen. People taking XELJANZ 5 mg twice daily or XELJANZ 10 mg twice daily have a higher risk of certain cancers including lymphoma and lung cancer, especially if you are a current or past smoker. Tell your healthcare provider if you have ever had any type of cancer.

Higher dose. People with ulcerative colitis taking the higher dose of XELJANZ (10 mg twice daily) or XELJANZ XR (22 mg one time each day) have a higher risk of serious infections, shingles, or skin cancers.

Immune system problem. Some people who have taken XELJANZ with certain other medicines to prevent kidney transplant rejection have had a problem with certain white blood cells growing out of control (Epstein Barr Virus–associated post-transplant lymphoproliferative disorder).

Increased risk of major cardiovascular events such as heart attack, stroke or death in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking XELJANZ 5 mg twice daily or XELJANZ 10 mg twice daily, especially if you are a current or past smoker.

Get emergency help right away if you have any symptoms of a heart attack or stroke while taking XELJANZ, including:

discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
pain or discomfort in your arms, back, neck, jaw, or stomach
shortness of breath with or without chest discomfort
breaking out in a cold sweat
nausea or vomiting
feeling lightheaded
weakness in one part or on one side of your body
slurred speech

Blood clots in the lungs (pulmonary embolism, PE), veins of the legs (deep vein thrombosis, DVT), and arteries (arterial thrombosis) have happened more often in people who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking XELJANZ 5 mg twice daily or XELJANZ 10 mg twice daily. Blood clots in the lungs have also happened in people with ulcerative colitis. Some people have died from these blood clots.

Stop taking XELJANZ and tell your healthcare provider right away if you have any signs and symptoms of blood clots such as sudden shortness of breath, difficulty breathing, chest pain, swelling of a leg or arm, leg pain or tenderness, or red or discolored skin in the leg or arm.

Tears (perforation) in the stomach or intestines. Tell your healthcare provider if you have had diverticulitis (inflammation in parts of the large intestine) or ulcers in your stomach or intestines. Some people taking XELJANZ can get tears in their stomach or intestine. This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate. Tell your healthcare provider right away if you have fever, stomach-area pain that does not go away, and a change in your bowel habits.

Serious allergic reactions can occur. Stop using XELJANZ and call your healthcare provider right away if you have swelling of your lips, tongue, throat, or get hives.

Changes in certain lab test results. Your doctor should do blood tests to check your white and red blood cells before starting and while you are taking XELJANZ. Your doctor should also check certain liver tests. You should not take XELJANZ if your lymphocyte count, neutrophil count, or red blood cell count is too low or your liver function test levels are too high. Changes in lab test results may cause your healthcare provider to stop your XELJANZ treatment for a time. Your cholesterol levels should be checked 4 to 8 weeks after you start receiving XELJANZ.

Before you use XELJANZ, tell your healthcare provider if you:

Are being treated for an infection, have an infection that won’t go away or keeps coming back, or think you have symptoms of an infection
Have TB, or have been in close contact with someone with TB, or were born in, lived in, or traveled where there is more risk for getting TB
Have diabetes, chronic lung disease, HIV, or a weak immune system. People with these conditions have a higher chance for infections
Live or have lived in certain areas (such as Ohio and Mississippi River Valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections
Have or have had Hepatitis B or C
Are a current or past smoker
Have had any type of cancer
Have had a heart attack, other heart problems or stroke
Have had blood clots
Have liver or kidney problems
Have any stomach area (abdominal) pain or been diagnosed with diverticulitis or ulcers in your stomach or intestines
Have recently received or plan to receive a vaccine. People taking XELJANZ should not receive live vaccines but can receive non-live vaccines
Are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed. You should not take XELJANZ and breastfeed
Have had a reaction to tofacitinib or any of the ingredients
Are taking other medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take any of the following medicines while taking XELJANZ since this may increase your risk of infection:
- tocilizumab (Actemra^®)
- etanercept (Enbrel^®)
- adalimumab (Humira^®)
- infliximab (Remicade^®)
- rituximab (Rituxan^®)
- abatacept (Orencia^®)
- anakinra (Kineret^®)
- certolizumab (Cimzia^®)
- golimumab (Simponi^®)
- ustekinumab (Stelara^®)
- secukinumab (Cosentyx^®)
- vedolizumab (Entyvio^®)
- ixekizumab (Taltz^®)
- sarilumab (Kevzara^®)
- azathioprine, cyclosporine, or other immunosuppressive drugs
Tell your healthcare provider if you are taking medicines that affect the way certain liver enzymes work. Ask your healthcare provider if you are not sure if your medicine is one of these.

What are other possible side effects of XELJANZ/XELJANZ XR?

If you are a carrier of the Hepatitis B or C virus (viruses that affect the liver), the virus may become active while you use XELJANZ. Your healthcare provider may do blood tests before starting and while using treatment with XELJANZ. Tell your healthcare provider if you have any signs of these symptoms: feel very tired, little or no appetite, clay-colored bowel movements, chills, muscle aches, skin rash, skin or eyes look yellow, vomiting, fevers, stomach discomfort, or dark urine.

Common side effects in people with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis include upper respiratory tract infections (common cold, sinus infections), headache, diarrhea, nasal congestion, sore throat, runny nose (nasopharyngitis), and high blood pressure (hypertension).

Common side effects in people with ulcerative colitis include nasal congestion, sore throat, runny nose (nasopharyngitis), increased cholesterol levels, headache, upper respiratory tract infections (common cold, sinus infections), increased muscle enzyme levels, rash, diarrhea, and shingles (herpes zoster).

Common side effects in children (2 & older) with polyarticular course juvenile arthritis include upper respiratory tract infections (common cold, sinus infections), nasal congestion, sore throat, and runny nose (nasopharyngitis), headache, fever, nausea, and vomiting.

XELJANZ & Pregnancy

XELJANZ may affect the ability of females to get pregnant. It is not known if this will change after stopping XELJANZ. It is not known if XELJANZ will harm an unborn baby.

Pregnancy Registry: Pfizer has a registry for pregnant women who take XELJANZ. The purpose of this registry is to check the health of the pregnant mother and her baby. If you are pregnant or become pregnant while taking XELJANZ, talk to your healthcare provider about how you can join this pregnancy registry or you may contact the registry at 1-877-311-8972 to enroll.

You and your healthcare provider should decide if you will take XELJANZ or breastfeed. You should not do both. After you stop your treatment with XELJANZ do not start breastfeeding again until 18 hours after your last dose of XELJANZ or 36 hours after your last dose of XELJANZ XR.

The safety information above applies to all marketed formulations of XELJANZ. Specific risks associated with certain dosing are noted.

Please see full Prescribing Information, including BOXED WARNING and Medication Guide.

Indications

XELJANZ/XELJANZ XR (tofacitinib) is used to treat adults who have tried TNF blockers with:

Moderately to severely active rheumatoid arthritis when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or cannot be tolerated
Active psoriatic arthritis when 1 or more tumor necrosis factor (TNF) blocker medicines have been used, and did not work well or cannot be tolerated
Moderately to severely active ulcerative colitis when 1 or more tumor necrosis factor (TNF) blocker medicines have been used, and did not work well or cannot be tolerated
Active ankylosing spondylitis when 1 or more tumor necrosis factor (TNF) blocker medicines have been used, and did not work well or cannot be tolerated

XELJANZ/XELJANZ Oral Solution is used to treat patients 2 years of age and older with:

Active polyarticular course juvenile arthritis when 1 or more tumor necrosis factor (TNF) blocker medicines have been used, and did not work well or cannot be tolerated

It is not known if XELJANZ/XELJANZ XR is safe and effective in people with Hepatitis B or C.

XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended for people with severe liver problems.

It is not known if XELJANZ/XELJANZ Oral Solution is safe and effective in children for treatment other than active polyarticular course juvenile arthritis.

It is not known if XELJANZ XR is safe and effective in children.

XELJANZ/XELJANZ XR (tofacitinib) is used to treat adults who have tried TNF blockers with:

Moderately to severely active rheumatoid arthritis when 1 or more medicines called tumor necrosis factor (TNF) blockers have...Read More

XELJANZ/XELJANZ XR (tofacitinib) is used to treat adults who have tried TNF blockers with:

Moderately to severely active rheumatoid » Read More

Important Safety Information

Serious infections. XELJANZ can lower the ability of your immune system to fight infections. Do not start taking XELJANZ if you have any kind of infection unless your healthcare provider tells you it is okay. Serious infections have happened in people taking XELJANZ. These serious infections include tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider should test you for TB before starting and during treatment with XELJANZ. You should not start taking XELJANZ if you have any kind of infection unless your healthcare professional tells you it is okay.

Before and after starting XELJANZ, tell your doctor if you are being treated for an infection, have infections that keep coming back, or have symptoms of an infection, including:

fever, sweating, or chills
cough
blood in phlegm
warm, red, or painful skin or sores on your body
burning when you urinate
urinating more often than normal
muscle aches
shortness of breath
weight loss
diarrhea or stomach pain
feeling very tired

Increased risk of death in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking XELJANZ 5 mg twice daily or XELJANZ 10 mg twice daily.

Cancer. XELJANZ may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers, including skin cancers, can happen. People taking XELJANZ 5 mg twice daily or XELJANZ 10 mg twice daily have a higher risk of certain cancers including lymphoma and lung cancer, especially if you are a current or past smoker. Tell your healthcare provider if you have ever had any type of cancer.

Higher dose. People with ulcerative colitis taking the higher dose of XELJANZ (10 mg twice daily) or XELJANZ XR (22 mg one time each day) have a higher risk of serious infections, shingles, or skin cancers.

Immune system problem. Some people who have taken XELJANZ with certain other medicines to prevent kidney transplant rejection have had a problem with certain white blood cells growing out of control (Epstein Barr Virus–associated post-transplant lymphoproliferative disorder).

Increased risk of major cardiovascular events such as heart attack, stroke or death in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking XELJANZ 5 mg twice daily or XELJANZ 10 mg twice daily, especially if you are a current or past smoker.

Get emergency help right away if you have any symptoms of a heart attack or stroke while taking XELJANZ, including:

discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
pain or discomfort in your arms, back, neck, jaw, or stomach
shortness of breath with or without chest discomfort
breaking out in a cold sweat
nausea or vomiting
feeling lightheaded
weakness in one part or on one side of your body
slurred speech

Blood clots in the lungs (pulmonary embolism, PE), veins of the legs (deep vein thrombosis, DVT), and arteries (arterial thrombosis) have happened more often in people who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking XELJANZ 5 mg twice daily or XELJANZ 10 mg twice daily. Blood clots in the lungs have also happened in people with ulcerative colitis. Some people have died from these blood clots.

Stop taking XELJANZ and tell your healthcare provider right away if you have any signs and symptoms of blood clots such as sudden shortness of breath, difficulty breathing, chest pain, swelling of a leg or arm, leg pain or tenderness, or red or discolored skin in the leg or arm.

Tears (perforation) in the stomach or intestines. Tell your healthcare provider if you have had diverticulitis (inflammation in parts of the large intestine) or ulcers in your stomach or intestines. Some people taking XELJANZ can get tears in their stomach or intestine. This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate. Tell your healthcare provider right away if you have fever, stomach-area pain that does not go away, and a change in your bowel habits.

Serious allergic reactions can occur. Stop using XELJANZ and call your healthcare provider right away if you have swelling of your lips, tongue, throat, or get hives.

Changes in certain lab test results. Your doctor should do blood tests to check your white and red blood cells before starting and while you are taking XELJANZ. Your doctor should also check certain liver tests. You should not take XELJANZ if your lymphocyte count, neutrophil count, or red blood cell count is too low or your liver function test levels are too high. Changes in lab test results may cause your healthcare provider to stop your XELJANZ treatment for a time. Your cholesterol levels should be checked 4 to 8 weeks after you start receiving XELJANZ.

Before you use XELJANZ, tell your healthcare provider if you:

Are being treated for an infection, have an infection that won’t go away or keeps coming back, or think you have symptoms of an infection
Have TB, or have been in close contact with someone with TB, or were born in, lived in, or traveled where there is more risk for getting TB
Have diabetes, chronic lung disease, HIV, or a weak immune system. People with these conditions have a higher chance for infections
Live or have lived in certain areas (such as Ohio and Mississippi River Valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections
Have or have had Hepatitis B or C
Are a current or past smoker
Have had any type of cancer
Have had a heart attack, other heart problems or stroke
Have had blood clots
Have liver or kidney problems
Have any stomach area (abdominal) pain or been diagnosed with diverticulitis or ulcers in your stomach or intestines
Have recently received or plan to receive a vaccine. People taking XELJANZ should not receive live vaccines but can receive non-live vaccines
Are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed. You should not take XELJANZ and breastfeed
Have had a reaction to tofacitinib or any of the ingredients
Are taking other medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take any of the following medicines while taking XELJANZ since this may increase your risk of infection:
- tocilizumab (Actemra^®)
- etanercept (Enbrel^®)
- adalimumab (Humira^®)
- infliximab (Remicade^®)
- rituximab (Rituxan^®)
- abatacept (Orencia^®)
- anakinra (Kineret^®)
- certolizumab (Cimzia^®)
- golimumab (Simponi^®)
- ustekinumab (Stelara^®)
- secukinumab (Cosentyx^®)
- vedolizumab (Entyvio^®)
- ixekizumab (Taltz^®)
- sarilumab (Kevzara^®)
- azathioprine, cyclosporine, or other immunosuppressive drugs
Tell your healthcare provider if you are taking medicines that affect the way certain liver enzymes work. Ask your healthcare provider if you are not sure if your medicine is one of these.

What are other possible side effects of XELJANZ/XELJANZ XR?

If you are a carrier of the Hepatitis B or C virus (viruses that affect the liver), the virus may become active while you use XELJANZ. Your healthcare provider may do blood tests before starting and while using treatment with XELJANZ. Tell your healthcare provider if you have any signs of these symptoms: feel very tired, little or no appetite, clay-colored bowel movements, chills, muscle aches, skin rash, skin or eyes look yellow, vomiting, fevers, stomach discomfort, or dark urine.

Common side effects in people with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis include upper respiratory tract infections (common cold, sinus infections), headache, diarrhea, nasal congestion, sore throat, runny nose (nasopharyngitis), and high blood pressure (hypertension).

Common side effects in people with ulcerative colitis include nasal congestion, sore throat, runny nose (nasopharyngitis), increased cholesterol levels, headache, upper respiratory tract infections (common cold, sinus infections), increased muscle enzyme levels, rash, diarrhea, and shingles (herpes zoster).

Common side effects in children (2 & older) with polyarticular course juvenile arthritis include upper respiratory tract infections (common cold, sinus infections), nasal congestion, sore throat, and runny nose (nasopharyngitis), headache, fever, nausea, and vomiting.

XELJANZ & Pregnancy

XELJANZ may affect the ability of females to get pregnant. It is not known if this will change after stopping XELJANZ. It is not known if XELJANZ will harm an unborn baby.

Pregnancy Registry: Pfizer has a registry for pregnant women who take XELJANZ. The purpose of this registry is to check the health of the pregnant mother and her baby. If you are pregnant or become pregnant while taking XELJANZ, talk to your healthcare provider about how you can join this pregnancy registry or you may contact the registry at 1-877-311-8972 to enroll.

You and your healthcare provider should decide if you will take XELJANZ or breastfeed. You should not do both. After you stop your treatment with XELJANZ do not start breastfeeding again until 18 hours after your last dose of XELJANZ or 36 hours after your last dose of XELJANZ XR.

The safety information above applies to all marketed formulations of XELJANZ. Specific risks associated with certain dosing are noted.

Please see full Prescribing Information, including BOXED WARNING and Medication Guide.

Indications

XELJANZ/XELJANZ XR (tofacitinib) is used to treat adults who have tried TNF blockers with:

Moderately to severely active rheumatoid arthritis when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or cannot be tolerated
Active psoriatic arthritis when 1 or more tumor necrosis factor (TNF) blocker medicines have been used, and did not work well or cannot be tolerated
Moderately to severely active ulcerative colitis when 1 or more tumor necrosis factor (TNF) blocker medicines have been used, and did not work well or cannot be tolerated
Active ankylosing spondylitis when 1 or more tumor necrosis factor (TNF) blocker medicines have been used, and did not work well or cannot be tolerated

XELJANZ/XELJANZ Oral Solution is used to treat patients 2 years of age and older with:

Active polyarticular course juvenile arthritis when 1 or more tumor necrosis factor (TNF) blocker medicines have been used, and did not work well or cannot be tolerated

It is not known if XELJANZ/XELJANZ XR is safe and effective in people with Hepatitis B or C.

XELJANZ/XELJANZ XR/XELJANZ Oral Solution is not recommended for people with severe liver problems.

It is not known if XELJANZ/XELJANZ Oral Solution is safe and effective in children for treatment other than active polyarticular course juvenile arthritis.

It is not known if XELJANZ XR is safe and effective in children.

Important Safety Information

Serious infections. XELJANZ can lower the ability of your immune system to fight infections. Do not start taking XELJANZ if you have any kind of infection unless your healthcare provider tells you it is okay. Serious infections have happened in people taking XELJANZ. These serious infections include tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider should test you for TB before starting and during treatment with XELJANZ. You should not start taking XELJANZ if you have any kind of infection unless your healthcare professional tells you it is okay.

Before and after starting XELJANZ, tell your doctor if you are being treated for an infection, have infections that keep coming back, or have symptoms of an infection, including:

fever, sweating, or chills
cough
blood in phlegm
warm, red, or painful skin or sores on your body
burning when you urinate
urinating more often than normal
muscle aches
shortness of breath
weight loss
diarrhea or stomach pain
feeling very tired

Increased risk of death in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking XELJANZ 5 mg twice daily or XELJANZ 10 mg twice daily.

Cancer. XELJANZ may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers, including skin cancers, can happen. People taking XELJANZ 5 mg twice daily or XELJANZ 10 mg twice daily have a higher risk of certain cancers including lymphoma and lung cancer, especially if you are a current or past smoker. Tell your healthcare provider if you have ever had any type of cancer.

Higher dose. People with ulcerative colitis taking the higher dose of XELJANZ (10 mg twice daily) or XELJANZ XR (22 mg one time each day) have a higher risk of serious infections, shingles, or skin cancers.

Immune system problem. Some people who have taken XELJANZ with certain other medicines to prevent kidney transplant rejection have had a problem with certain white blood cells growing out of control (Epstein Barr Virus–associated post-transplant lymphoproliferative disorder).

Increased risk of major cardiovascular events such as heart attack, stroke or death in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and are taking XELJANZ 5 mg twice daily or XELJANZ 10 mg twice daily, especially if you are a current or past smoker.

Get emergency help right away if you have any symptoms of a heart attack or stroke while taking XELJANZ, including:

discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
pain or discomfort in your arms, back, neck, jaw, or stomach
shortness of breath with or without chest discomfort
breaking out in a cold sweat
nausea or vomiting
feeling lightheaded
weakness in one part or on one side of your body
slurred speech

Blood clots in the lungs (pulmonary embolism, PE), veins of the legs (deep vein thrombosis, DVT), and arteries (arterial thrombosis) have happened more often in people who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking XELJANZ 5 mg twice daily or XELJANZ 10 mg twice daily. Blood clots in the lungs have also happened in people with ulcerative colitis. Some people have died from these blood clots.

Stop taking XELJANZ and tell your healthcare provider right away if you have any signs and symptoms of blood clots such as sudden shortness of breath, difficulty breathing, chest pain, swelling of a leg or arm, leg pain or tenderness, or red or discolored skin in the leg or arm.

Tears (perforation) in the stomach or intestines. Tell your healthcare provider if you have had diverticulitis (inflammation in parts of the large intestine) or ulcers in your stomach or intestines. Some people taking XELJANZ can get tears in their stomach or intestine. This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate. Tell your healthcare provider right away if you have fever, stomach-area pain that does not go away, and a change in your bowel habits.

Serious allergic reactions can occur. Stop using XELJANZ and call your healthcare provider right away if you have swelling of your lips, tongue, throat, or get hives.

Changes in certain lab test results. Your doctor should do blood tests to check your white and red blood cells before starting and while you are taking XELJANZ. Your doctor should also check certain liver tests. You should not take XELJANZ if your lymphocyte count, neutrophil count, or red blood cell count is too low or your liver function test levels are too high. Changes in lab test results may cause your healthcare provider to stop your XELJANZ treatment for a time. Your cholesterol levels should be checked 4 to 8 weeks after you start receiving XELJANZ.

Before you use XELJANZ, tell your healthcare provider if you:

Are being treated for an infection, have an infection that won’t go away or keeps coming back, or think you have symptoms of an infection
Have TB, or have been in close contact with someone with TB, or were born in, lived in, or traveled where there is more risk for getting TB
Have diabetes, chronic lung disease, HIV, or a weak immune system. People with these conditions have a higher chance for infections
Live or have lived in certain areas (such as Ohio and Mississippi River Valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections
Have or have had Hepatitis B or C
Are a current or past smoker
Have had any type of cancer
Have had a heart attack, other heart problems or stroke
Have had blood clots
Have liver or kidney problems
Have any stomach area (abdominal) pain or been diagnosed with diverticulitis or ulcers in your stomach or intestines
Have recently received or plan to receive a vaccine. People taking XELJANZ should not receive live vaccines but can receive non-live vaccines
Are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed. You should not take XELJANZ and breastfeed
Have had a reaction to tofacitinib or any of the ingredients
Are taking other medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take any of the following medicines while taking XELJANZ since this may increase your risk of infection:
- tocilizumab (Actemra^®)
- etanercept (Enbrel^®)
- adalimumab (Humira^®)
- infliximab (Remicade^®)
- rituximab (Rituxan^®)
- abatacept (Orencia^®)
- anakinra (Kineret^®)
- certolizumab (Cimzia^®)
- golimumab (Simponi^®)
- ustekinumab (Stelara^®)
- secukinumab (Cosentyx^®)
- vedolizumab (Entyvio^®)
- ixekizumab (Taltz^®)
- sarilumab (Kevzara^®)
- azathioprine, cyclosporine, or other immunosuppressive drugs
Tell your healthcare provider if you are taking medicines that affect the way certain liver enzymes work. Ask your healthcare provider if you are not sure if your medicine is one of these.

What are other possible side effects of XELJANZ/XELJANZ XR?

If you are a carrier of the Hepatitis B or C virus (viruses that affect the liver), the virus may become active while you use XELJANZ. Your healthcare provider may do blood tests before starting and while using treatment with XELJANZ. Tell your healthcare provider if you have any signs of these symptoms: feel very tired, little or no appetite, clay-colored bowel movements, chills, muscle aches, skin rash, skin or eyes look yellow, vomiting, fevers, stomach discomfort, or dark urine.

Common side effects in people with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis include upper respiratory tract infections (common cold, sinus infections), headache, diarrhea, nasal congestion, sore throat, runny nose (nasopharyngitis), and high blood pressure (hypertension).

Common side effects in people with ulcerative colitis include nasal congestion, sore throat, runny nose (nasopharyngitis), increased cholesterol levels, headache, upper respiratory tract infections (common cold, sinus infections), increased muscle enzyme levels, rash, diarrhea, and shingles (herpes zoster).

Common side effects in children (2 & older) with polyarticular course juvenile arthritis include upper respiratory tract infections (common cold, sinus infections), nasal congestion, sore throat, and runny nose (nasopharyngitis), headache, fever, nausea, and vomiting.

XELJANZ & Pregnancy

XELJANZ may affect the ability of females to get pregnant. It is not known if this will change after stopping XELJANZ. It is not known if XELJANZ will harm an unborn baby.

Pregnancy Registry: Pfizer has a registry for pregnant women who take XELJANZ. The purpose of this registry is to check the health of the pregnant mother and her baby. If you are pregnant or become pregnant while taking XELJANZ, talk to your healthcare provider about how you can join this pregnancy registry or you may contact the registry at 1-877-311-8972 to enroll.

You and your healthcare provider should decide if you will take XELJANZ or breastfeed. You should not do both. After you stop your treatment with XELJANZ do not start breastfeeding again until 18 hours after your last dose of XELJANZ or 36 hours after your last dose of XELJANZ XR.

The safety information above applies to all marketed formulations of XELJANZ. Specific risks associated with certain dosing are noted.

Please see full Prescribing Information, including BOXED WARNING and Medication Guide.

Pay as little as $0 per month for your XELJANZ prescription*

Eligibility required. Annual savings of $6,000–$15,000. Federal and state healthcare beneficiaries ineligible. No membership fee. Offer not valid for cash paying patients. Terms and conditions apply.

Eligibility required. Annual savings of $6,000–$15,000. Federal and state healthcare beneficiaries ineligible. No membership fee. Offer not valid for cash paying patients. Terms and conditions apply.

Sign Up